Direxion Daily Pharmaceutical & Medical Bull 3X ETF (NYSEARCA:PILL – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 41,214 shares, an increase of 130.5% from the September 30th total of 17,878 shares. Currently, 3.9% of the company’s shares are sold short. Based on an average daily volume of 47,940 shares, the days-to-cover ratio is presently 0.9 days.
Direxion Daily Pharmaceutical & Medical Bull 3X ETF Trading Down 2.8%
Shares of PILL stock traded down $0.44 during mid-day trading on Friday, reaching $15.21. The stock had a trading volume of 238,192 shares, compared to its average volume of 79,377. The firm has a market capitalization of $15.97 million, a PE ratio of 10.33 and a beta of 1.79. The stock’s 50-day moving average price is $17.39 and its two-hundred day moving average price is $14.85. Direxion Daily Pharmaceutical & Medical Bull 3X ETF has a 52-week low of $7.74 and a 52-week high of $24.15.
About Direxion Daily Pharmaceutical & Medical Bull 3X ETF
The Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL) is an exchange-traded fund that is based on the S&P Pharmaceuticals Select Industry index. The fund provides 3x daily exposure to a modified equal-weighted index of pharmaceutical companies in the US. PILL was launched on Nov 15, 2017 and is managed by Direxion.
See Also
- Five stocks we like better than Direxion Daily Pharmaceutical & Medical Bull 3X ETF
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Direxion Daily Pharmaceutical & Medical Bull 3X ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Direxion Daily Pharmaceutical & Medical Bull 3X ETF and related companies with MarketBeat.com's FREE daily email newsletter.
